Literature DB >> 17878365

CS1 (CRACC, CD319) induces proliferation and autocrine cytokine expression on human B lymphocytes.

Jae Kyung Lee1, Stephen O Mathew, Swapnil V Vaidya, Pappanaicken R Kumaresan, Porunelloor A Mathew.   

Abstract

CS1 (CRACC, CD319), a member of the CD2 family of cell surface receptors, is implicated in the activation of NK cell-mediated cytotoxicity. Previous studies showed that CS1 is also expressed on activated B cells. However, the functional role of CS1 in human B-lymphocytes is not known. Two isoforms of CS1, CS1-L and CS1-S, are expressed in human NK cells that differentially regulate NK cell function. CS1-L contains immunoreceptor tyrosine-based switch motifs in its cytoplasmic domain whereas CS1-S lacks immunoreceptor tyrosine-based switch motifs. In this study, we show that human B lymphocytes express only the CS1-L isoform, and its expression is up-regulated upon B cell activation with various stimulators. Moreover, anti-CS1 mAb strongly enhanced proliferation of both freshly isolated as well as activated B cells. The enhanced proliferation effects of CS1 were most prominent on B cells activated by anti-CD40 mAbs and/or hrIL-4. The effects of CS1 on B cell proliferation were shown on both naive and memory B cells. Human cytokine microarray and quantitative real-time PCR results indicated that CS1 activation enhanced mRNA transcripts of flt3 ligand, lymphotoxin A, TNF, and IL-14. Neutralizing Abs against lymphotoxin A, TNF-alpha, and/or flt3 ligand abolished the ability of CS1 on the B cell proliferation. These results suggest that activation of B lymphocytes, through surface CS1, may be mediated through secretion of autocrine cytokines and CS1 may play a role in the regulation of B lymphocyte proliferation during immune responses.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17878365     DOI: 10.4049/jimmunol.179.7.4672

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  28 in total

1.  Altered expression of signalling lymphocyte activation molecule (SLAM) family receptors CS1 (CD319) and 2B4 (CD244) in patients with systemic lupus erythematosus.

Authors:  J R Kim; S O Mathew; R K Patel; R M Pertusi; P A Mathew
Journal:  Clin Exp Immunol       Date:  2010-03-16       Impact factor: 4.330

2.  Immune cell inhibition by SLAMF7 is mediated by a mechanism requiring src kinases, CD45, and SHIP-1 that is defective in multiple myeloma cells.

Authors:  Huaijian Guo; Mario-Ernesto Cruz-Munoz; Ning Wu; Michael Robbins; André Veillette
Journal:  Mol Cell Biol       Date:  2014-10-13       Impact factor: 4.272

3.  Repository corticotrophin injection exerts direct acute effects on human B cell gene expression distinct from the actions of glucocorticoids.

Authors:  A L Benko; C A McAloose; P M Becker; D Wright; T Sunyer; Y I Kawasawa; N J Olsen; W J Kovacs
Journal:  Clin Exp Immunol       Date:  2018-01-12       Impact factor: 4.330

4.  Alternative splicing and mRNA expression analysis of bovine SLAMF7 gene in healthy and mastitis mammary tissues.

Authors:  Zhihua Ju; Changfa Wang; Qiuling Li; Minghai Hou; Shuai Gao; Qinlei Hou; Jianbin Li; Jinming Huang; Jifeng Zhong
Journal:  Mol Biol Rep       Date:  2011-07-17       Impact factor: 2.316

5.  A CD8α- Subset of CD4+SLAMF7+ Cytotoxic T Cells Is Expanded in Patients With IgG4-Related Disease and Decreases Following Glucocorticoid Treatment.

Authors:  Emanuel Della-Torre; Emanuele Bozzalla-Cassione; Clara Sciorati; Eliana Ruggiero; Marco Lanzillotta; Silvia Bonfiglio; Hamid Mattoo; Cory A Perugino; Enrica Bozzolo; Lucrezia Rovati; Paolo Giorgio Arcidiacono; Gianpaolo Balzano; Dejan Lazarevic; Chiara Bonini; Massimo Falconi; John H Stone; Lorenzo Dagna; Shiv Pillai; Angelo A Manfredi
Journal:  Arthritis Rheumatol       Date:  2018-05-20       Impact factor: 10.995

Review 6.  CS1 (SLAMF7, CD319) is an effective immunotherapeutic target for multiple myeloma.

Authors:  Joseph D Malaer; Porunelloor A Mathew
Journal:  Am J Cancer Res       Date:  2017-08-01       Impact factor: 6.166

7.  De novo oligoclonal expansions of circulating plasmablasts in active and relapsing IgG4-related disease.

Authors:  Hamid Mattoo; Vinay S Mahajan; Emanuel Della-Torre; Yurie Sekigami; Mollie Carruthers; Zachary S Wallace; Vikram Deshpande; John H Stone; Shiv Pillai
Journal:  J Allergy Clin Immunol       Date:  2014-05-06       Impact factor: 10.793

8.  Multiple myeloma phosphotyrosine proteomic profile associated with FGFR3 expression, ligand activation, and drug inhibition.

Authors:  Jonathan R St-Germain; Paul Taylor; Jiefei Tong; Lily L Jin; Ana Nikolic; Ian I Stewart; Robert M Ewing; Moyez Dharsee; Zhihua Li; Suzanne Trudel; Michael F Moran
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-09       Impact factor: 11.205

9.  CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells.

Authors:  Yu-Tzu Tai; Ender Soydan; Weihua Song; Mariateresa Fulciniti; Kihyun Kim; Fangxin Hong; Xian-Feng Li; Peter Burger; Matthew J Rumizen; Sabikun Nahar; Klaus Podar; Teru Hideshima; Nikhil C Munshi; Giovanni Tonon; Ruben D Carrasco; Daniel E H Afar; Kenneth C Anderson
Journal:  Blood       Date:  2009-02-04       Impact factor: 22.113

10.  Differential expression of Aedes aegypti salivary transcriptome upon blood feeding.

Authors:  Saravanan Thangamani; Stephen K Wikel
Journal:  Parasit Vectors       Date:  2009-07-24       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.